SEC Tracker
Get the app

Estrella Immunopharma ESLA

Estrella Immunopharma: signs a material agreement, completes an acquisition or sale of assets and 9 other items

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Takes on a new financial obligation (2.03)
  • Reports an exchange listing deficiency notice (3.01)
  • Sells unregistered shares (3.02)
  • Changes shareholder rights (3.03)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Changes its ethics code (5.05)
  • Changes its shell company status (5.06)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Estrella Immunopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Fibrogen FGEN public float $21M, Jun 30, 2025
  2. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  3. Imunon IMNN public float $21M, Jun 30, 2025
  4. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  5. Dare Bioscience DARE public float $21M, Jun 30, 2025